ACA
VRTX icon

Aptus Capital Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Aptus Capital Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.85M Sell
13,787
-857
-6% -$380K 0.05% 303
2026
Q1 		$6.54M Sell
14,644
-1,798
-11% -$838K 0.05% 294
2025
Q4 		$7.45M Buy
16,442
+687
+4% +$296K 0.05% 261
2025
Q3 		$6.17M Buy
15,755
+1,868
+13% +$781K 0.04% 287
2025
Q2 		$6.18M Sell
13,887
-10,353
-43% -$4.77M 0.05% 268
2025
Q1 		$11.8M Buy
24,240
+2,072
+9% +$966K 0.12% 159
2024
Q4 		$8.93M Buy
22,168
+3,452
+18% +$1.6M 0.09% 182
2024
Q3 		$8.7M Buy
18,716
+3,071
+20% +$1.48M 0.13% 149
2024
Q2 		$7.33M Buy
15,645
+3,305
+27% +$1.43M 0.13% 145
2024
Q1 		$5.16M Buy
12,340
+10,615
+615% +$4.49M 0.1% 178
2023
Q4 		$702K Sell
1,725
-47
-3% -$17.4K 0.02% 329
2023
Q3 		$616K Buy
1,772
+698
+65% +$244K 0.02% 347
2023
Q2 		$378K Buy
1,074
+41
+4% +$13.8K 0.01% 358
2023
Q1 		$325K Sell
1,033
-333
-24% -$99.9K 0.01% 379
2022
Q4 		$394K Buy
1,366
+115
+9% +$35K 0.01% 374
2022
Q3 		$362K Buy
1,251
+229
+22% +$65.9K 0.01% 362
2022
Q2 		$288K Sell
1,022
-13
-1% -$3.48K 0.01% 330
2022
Q1 		$270K Buy
+1,035
New +$246K 0.01% 376

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Aptus Capital Advisors's VRTX Position: Q2 2026 in Review

Aptus Capital Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 5.9% in Q2 2026, selling an estimated $380K and leaving 13,787 shares worth $6.85M. The position accounts for 0.05% of the portfolio, ranked #303.

Aptus Capital Advisors first reported a position in VRTX in Q1 2022 and has held it in 18 quarters since. The position peaked at $11.8M in Q1 2025. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Aptus Capital Advisors held 13,787 shares of Vertex Pharmaceuticals worth $6.85M as of Q2 2026.
  • Aptus Capital Advisors sold 857 Vertex Pharmaceuticals shares in Q2 2026, an estimated $380K.
  • Vertex Pharmaceuticals made up 0.05% of Aptus Capital Advisors's portfolio in Q2 2026, its #303 holding.
  • Aptus Capital Advisors first reported a position in Vertex Pharmaceuticals in Q1 2022 and has held it in 18 quarters since.
  • Aptus Capital Advisors's Vertex Pharmaceuticals position peaked at $11.8M in Q1 2025.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Aptus Capital Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.